Chemokine axes have been shown to mediate sitespecific metastasis in breast cancer, but their relevance to different subtypes has been hardly addressed. Here, with the focus on the CCR7-CCL21 axis, patient datasets demonstrated that luminal-A tumors express relatively low CCR7 levels compared with more aggressive disease subtypes. Furthermore, lymph node metastasis was not associated with high CCR7 levels in luminal-A patients. The metastatic pattern of luminal-A breast tumors may be influenced by the way luminal-A tumor cells interpret signals provided by factors of the primary tumor microenvironment. Thus, CCR7-expressing human luminal-A cells were stimulated simultaneously by factors representing 3 tumor microenvironment arms typical of luminal-A tumors, hormonal, inflammatory, and growth stimulating: estrogen + TNF-a + epidermal growth factor. Such tumor microenvironment stimulation downregulated the migration of CCR7-expressing tumor cells toward CCL21 and inhibited the formation of directional protrusions toward CCL21 in a novel 3-dimensional hydrogel system. CCL21-induced migration of CCR7expressing tumor cells depended on PI3K and MAPK activation; however, when CCR7-expressing cancer cells were prestimulated by tumor microenvironment factors, CCL21 could not effectively activate these signaling pathways. In vivo, pre-exposure of the tumor cells to tumor microenvironment factors has put restraints on CCL21-mediated lymph node-homing cues and shifted the metastatic pattern of CCR7-expressing cells to the aggressive phenotype of dissemination to bones. Several of the aspects were also studied in the CXCR4-CXCL12 system, demonstrating similar patient and in vitro findings. Thus, we provide novel evidence to subtype-specific regulation of the CCR7-CCL21 axis, with more general implications to chemokine-dependent patterns of metastatic spread, revealing differential regulation in the luminal-A subtype.
Introduction
Distant metastases, rather than the primary tumor, are the principal cause of death of most cancer patients.
The formation of site-specific metastases is largely dictated by chemokine receptors and their respective ligands. Cancer cells expressing specific chemokine receptors home to organs constitutively expressing their corresponding chemokines, which then become preferred metastatic sites [1] [2] [3] . For example, dissemination of breast tumor cells to remote organs (bones, lungs, liver) is mostly governed by the CXCR4-CXCL12 pair [4] [5] [6] [7] . In parallel, tumor cells undergoing lymphatic dissemination [8] take advantage mainly of the CCR7-CCL21 axis [6, [9] [10] [11] [12] that normally is mostly used by DCs [13] [14] [15] . Findings in this field suggest that cancer cells mimic the directional process taken by licensed, CCR7-expressing DCs when they cross the floor of the subcapsular sinus and enter the CCL21-enriched T cell zone of the LN [13] [14] [15] . Of the 2 CCR7 ligands, CCL21 and CCL19, CCL21 has more robust activities in DC migration [14] [15] [16] [17] and is the most investigated in cancer.
The above chemokine-driven axes have been proposed to determine site-specific metastasis and to be of potential therapeutic relevance in breast cancer; however, breast cancer is not a single disease but rather a complex of heterogeneous entities that express very distinct clinical, morphologic, and molecular characteristics with a strong impact on disease progression (e.g., subtypes known as luminal-A, luminal-B, triplenegative, HER2+; the triple-negative subtype is often interchanged with "basal" [18, 19] ). Different subtypes of breast cancer also have divergent patterns of metastatic dissemination and of preferred metastatic organs. In general, the frequency of patients with LN metastasis is lower in the luminal-A subtype than in other disease subtypes. This is particularly so when luminal-A tumors are compared with the luminal-B subtype that shares several molecular characteristics with it [20] [21] [22] [23] [24] [25] [26] . In contrast, bone metastases are prevalent in luminal-A patients more than in other subtypes, and bones are the preferred metastatic site in this subtype of disease [23, 26, 27] .
To date, the roles of chemokine axes in breast cancer have not been thoroughly dissected in specific disease subtypes, and the mechanisms dictating the metastatic pattern of luminal-A tumors are far from being fully elucidated. Although patients belonging to this large subgroup demonstrate a relatively favorable outcome [18, 20, 28, 29] , a significant proportion of the patients will relapse. Once patients develop remote metastases, survival rates are still staggeringly low [27] (although steadily improving throughout the years [30] ), emphasizing the need to provide improved insights to the mechanisms contributing to metastatic spread in luminal-A patients.
To identify the roles of chemokines and their receptors in determining the metastatic patterns taken by luminal-A breast tumor cells, we found it relevant to study CCR7-and CXCR4mediated axes, as both receptors were found to be expressed by breast tumor cells by IHC [7, 9, [31] [32] [33] ). As an instigating step of metastatic dissemination, we were particularly interested in LN metastasis and in the roles of the CCR7-CCL21 axis in lymphatic dissemination; however, to determine if the findings may have more general implications, we also addressed some of the aspects with respect to the CXCR4-CXCL12 axis, a key determinant of site-specific metastasis that may impact also LN metastasis [4] [5] [6] [7] 34] .
For a high-throughput analysis of CCR7/CXCR4 expression levels and their association with metastasis, we used the METABRIC dataset of breast cancer patients [35] , as do many other researchers in the field [36] [37] [38] . This dataset provides a large cohort, in which changes in CCR7/CXCR4 expression could be determined quantitatively with high sensitivity, providing more robust results than IHC studies. The findings indicated that tumors of luminal-A breast cancer patients (ER+, PR +/2 , HER22, Ki-67 low [18, 19] ) express relatively low CCR7/CXCR4 levels and suggested that these chemokine axes do not play a key role in directing LN metastasis in this subtype of disease.
These findings point to unique regulatory pathways taking place in luminal-A breast tumors, which do not adhere to current dogmas. We hypothesized that the metastatic pattern taken by luminal-A breast tumor cells is influenced by signals provided by the primary TME and by the way luminal-A tumor cells interpret them. Thus, we analyzed the impacts of TME-driven stimuli on the responses of CCR7-expressing luminal-A breast tumor cells to CCL21 chemotactic gradients in vitro and in vivo. The TME stimulus was induced by simultaneous exposure of luminal-A breast tumor cells to representatives of 3 relevant arms of the TME: 1) estrogen, the key hormonal factor in luminal-A tumors, which by definition, all express ER [18, 19] ; 2) TNF-a, a representative of the inflammatory arm; this cytokine has direct tumor-promoting effects in breast cancer and is expressed by ;90% of breast cancer patients with recurrent disease, including ER+ breast tumors [39] [40] [41] [42] [43] ; and 3) EGF, a growth-stimulating factor that prevails in breast tumors [44, 45] . Luminal-A tumors express EGFR and are characterized by high levels of ErbB3 [46] [47] [48] . EGF was shown to act through EGFR-ErbB3 dimers in luminal-A breast tumor cells [46] and to induce signaling in such cells through indirect activation of ER [48] [49] [50] [51] [52] .
In a previous study, we have shown that the TME of primary breast tumors, represented by the estrogen + TNF-a + EGF stimulus (named "TME stimulation"), is a strong driver of metastasis in luminal-A breast tumor cells [53] . The combined stimulus of estrogen + TNF-a + EGF was much more effective than each factor alone in inducing metastasis-related functions in luminal-A breast tumor cells. These cells responded to this combined stimulus by increased release of angiogenic and proinflammatory factors, as well as matrix metalloproteinases; furthermore, they have exhibited an increased spreading and scattering phenotype, accompanied by formation of robust cellular protrusions [53] . In the present study, with the focus on the CCR7-CCL21 axis, we demonstrate that the same TME stimulus actually imposes constraints on the CCR7-mediated process of CCL21-induced tumor cell migration and of LN metastasis and shifts the metastatic pattern of luminal-A tumor cells toward the more aggressive pattern of metastasis in bones that are the prime metastatic sites in luminal-A breast cancer patients [23, 26, 27] .
Together with additional molecular analyses, our findings indicate that the CCR7-CCL21 pair is not a prime regulator of lymphatic dissemination in luminal-A breast cancer patients. Moreover, our findings regarding the CXCR4-CXCL12 axis-in patients and in some of the in vitro aspects-propose that a general modification in chemokine responses may take place in luminal-A breast tumor cells. Overall, in this study, we demonstrate disease subtype-specific regulation of chemokine-driven metastatic spread and provide a personalized context to this process in breast cancer metastasis.
MATERIALS AND METHODS

Patient dataset
Patient data analysis was performed with the METABRIC dataset [35] , including only samples that had a high content of tumor DNA (.70% of the sample DNA), classified in the dataset as the "high cellularity" cluster. The dataset comprised of gene expression and clinical characteristics of breast cancer patients divided into 6 groups: luminal-A (n = 338), luminal-B (n = 298), basal (largely corresponding to the "triple-negative" subtype; n = 168), HER2+ (n = 128), and "others" ["normal-like" (n = 38) and "NC" (n = 3)]. Tumors of the normal-like group are not well characterized; they are enriched with normal cells, and the cancer cells are suspected to be of the aggressive "claudin low" phenotype [35, 54] .
Patients were classified into the different subtypes, according to the PAM50 annotation file provided within the dataset, and the frequency of LN metastasis was statistically compared with x 2 test. In tables, patients were classified based on CCR7 expression or CXCR4 expression and were divided to quartiles, as described in the table legends. Proportions of luminal-A and  luminal-B patients with LN metastasis were compared by 2-sided x 2 test.  ILMN_1715131 was used as probe for CCR7 and ILMN_1801584 as probe for  CXCR4 .
Cell cultures
Here, we used the 2 most well-established luminal-A cell lines of human breast tumors: MCF-7 and T47D cells [55] [56] [57] . These 2 cell lines express the same setup of receptors that is required for response to TME stimulation, composed of estrogen + TNF-a + EGF [53] : 1) they express ER and respond to estrogen; 2) they express TNF-a receptors and respond to TNF-a; and 3) they respond to EGF, probably through the expression of EGFR [53, 56, [58] [59] [60] . MCF-7 cells were kindly provided by the late Dr. Alvin Kaye (Weizmann Institute of Science, Rehovot, Israel) and were authenticated as described previously [53] . T47D cells were provided by Dr. Iafa Keydar (Tel Aviv University, Tel Aviv, Israel), the researcher who generated this cell line [61] . The 2 cell lines were grown in culture, as described previously [53] .
Retroviral infections
To generate mCherry-expressing MCF-7 breast tumor cells, retroviral infections were performed as follows: human embryonic kidney 293 cells (a generous gift from Prof. Eran Bacharach, Tel Aviv University) were cotransfected by calcium phosphate with a combination of 10 mg retroviral mCherry-pQCXI plasmid (with a puromycin selection marker) and 10 mg plasmids encoding gag-pol and vesicular stomatitis virus-G (VSV-G) proteins. Supernatants were collected after 48 h, filtered through a 0.45 mm mesh, and incubated with MCF-7 cells in the presence of 8 mg/ml polybrene for 5 h. The infection process was repeated on the following day to increase infection yield. Seventy-two hours following the second infection process, mCherry-expressing MCF-7 cells were selected in 8 mg/ml puromycin (Cat. #P-1033; AG Scientific, San Diego, CA, USA) for 7 d.
Then, to generate CCR7-overexpressing MCF-7 cells, mCherry-expressing MCF-7 cells were infected as described above with CCR7-pQCXI or empty pQCXI vector as control (both with a neomycin selection marker). Similar processes were taken to generate CCR7-overexpressing T47D cells. In parallel, mCherry-expressing MCF-7 cells were infected in a separate procedure by CXCR4-pQCXI or empty pQCXI vector as control (both with a hygromycin selection marker). Seventy-two hours following infection, cells were selected in 1200 mg/ml G-418 (Cat. #G-1033; AG Scientific) or 2 mg/ml hygromycin (Cat. #ant-hg; InvivoGen, San Diego, CA, USA), as appropriate, for 14 d.
Stimulation by TME factors
Stimulation of breast tumor cells by factors of the TME (to be termed herein TME stimulation) was performed based on titration and kinetics analyses that were included in our previously published study [53] . In brief, MCF-7 and T47D cells were stimulated in vitro for 72 h (unless otherwise indicated) with the following 3 factors simultaneously: 1) estrogen (10 28 M; Cat. #E8875; Sigma-Aldrich, St. Louis, MO, USA); 2) TNF-a (50 ng/ml; Cat. #300-01A; PeproTech, Rocky Hill, NJ, USA); and 3) EGF (30 ng/ml; Cat. #236-EG; R&D Systems, Minneapolis, MN, USA). In all procedures, control cells were grown for the same time period in the presence of the diluents of the above factors. Stimulation was performed in phenol red-free and serum-free DMEM medium and was repeated daily.
Flow cytometry
CCR7 or CXCR4 expression on the cell surface of MCF-7 and/or T47D cells was determined by flow cytometry (FACS) using BD FACSort (BD Biosciences, San Jose, CA, USA) and mouse IgG2a antibodies against CCR7 (Cat. #MAB197; R&D Systems) or CXCR4 (Cat. #14-9999; eBioscience, San Diego, CA, USA), followed by FITC-conjugated antibodies against mouse IgG (Cat. #115-095-003; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Baseline staining was obtained by nonrelevant isotype-matched antibodies as controls. Staining patterns were determined using the WinMDI software.
Confocal microscopy
MCF-7 breast tumor cells that stably expressed CCR7, CXCR4, or the empty vectors as control were plated on coverslips in 24-well plates for 24 h. Then, plates were placed on ice, and the cells were washed with calcium and magnesium containing PBS (Cat. #02-020-1A; Biological Industries, Beit Haemek, Israel), blocked with 2% BSA, stained with antibodies against CCR7 and CXCR4 (as above) or nonrelevant isotype-matched controls, and then followed by Alexa Fluor 488-conjugated secondary antibodies against mouse IgG (Cat. #150109; Abcam, Cambridge, United Kingdom). In parallel, nuclei were visualized by Hoechst 33342 (Cat. #B2261; Sigma-Aldrich). Cells were fixed with 4% paraformaldehyde (Cat. #1.04005; Merck KGaA, Darmstadt, Germany), and coverslips were mounted using fluorescent-mounting medium (Cat. #E18-18; Golden Bridge International, Mukilteo, WA, USA) and analyzed with a Zeiss LSM 510-META confocal microscope (Carl Zeiss, Jena, Germany) at 363 magnification.
Cell migration assays
Migratory processes of MCF-7 and T47D cells were assayed in different time points in the range of 7-24 h. The 21 h time point was selected for migration studies performed in response to different concentrations of CCL21 (of CCR7-overexpressing cells or their empty vector controls) or of CXCL12 (of CXCR4-overexpressing cells or their empty vector controls). Dose-dependent migration assays (see relevant figures) were performed in 48-well modified Boyden chambers, in triplicates. The lower compartment of the chambers was loaded with rhCCL21 (Cat. #300-35, PeproTech; Cat. #366-6C, R&D Systems) or rhCXCL12 (Cat. #300-28A; PeproTech). The chemokines were diluted in medium containing 1% BSA and 25 mM Hepes buffer ("BSA medium"). The upper compartment of the chamber was loaded with tumor cells, also suspended in BSA medium. When relevant, cells were preincubated for 2 h in suspension with 20 mM LY294002 (PI3K inhibitor; Cat. #L9908; Sigma-Aldrich), 50 mM PD98059 (MAPK inhibitor, Cat. #10006726-10; Cayman Chemical, Ann Arbor, MI, USA), or DMSO (the solubilizer of the drugs). Inhibitors were also added to both the lower and upper compartments for the entire duration of migration assay. The 2 compartments were separated by an 8 mm polycarbonate PVPF filter (Cat. #K80SH58050; GE Membranes; Eastern Reverse Osmosis Systems, Wilmington, NC, USA), coated with 20 mg/ml fibronectin (Cat. #03-090; Biological Industries). The chamber was incubated for 21 h at 37°C in humidified air with 5% CO 2 . Then the filter was removed, cells were fixed and stained with Hemacolor staining set (Cat. #1.11661; Merck KGaA). Cells that had migrated to the underside of the filter in each of the triplicates were counted by light microscopy in 5 HPFs for each group. When appropriate, before migration assays, the tumor cells were exposed to TME stimulation for 72 h, as described above.
3D Hydrogels
MCF-7 breast tumor cells were cultured in 3D PEG-fibrinogen hydrogels. PEGfibrinogen precursor solution was prepared and cross-linked by photopolymerization, as described previously [62] . The hydrogels were prepared from PEGylated-fibrinogen at concentration of 6.5-7 mg/ml and a plateau shear storage modulus of 70 Pa (measured by AR-G2 parallel plate rheometer; TA Instruments, New Castle, DE, USA). First, a Teflon ring was attached to a glass coverslip (2 cm diameter) by Silicon grease and then manipulated as follows: 1) for assessing cellular morphology, the ring was loaded with mCherry-expressing tumor cells, suspended in the PEG-fibrinogen solution. After photopolymerization cross-linking, the entire structure (the hydrogel inside the ring and the coverslip) was moved into a well (in a 12-well plate). Medium containing TME stimulation (or diluents as control) was added on top of the hydrogels, which were then incubated at 37°C for 72 h. 2) For assessing directional response to CCL21 (see Supplemental Material), 25 ml PEG-fibrinogen precursor solution was mixed with 600 ng CCL21 (as above; PeproTech) and then placed on the coverslip in the center of the Teflon ring and cross-linked by photopolymerization. Subsequently, the ring was loaded with PEG-fibrinogen solution mixed with mCherry-expressing tumor cells that overexpressed CCR7 or the empty vector as control. After photopolymerization cross-linking, the entire structure was moved into a well. Medium containing TME stimulation (or diluents as control) was added on top of the hydrogels, which were then incubated at 37°C for 16 h (detailed reasons for shortening the incubation time are provided in Results, and see Fig. 4 
legend).
Following the construction of these 2 experimental setups (see 1 and 2 above), Z-stack images were obtained by confocal microscopy using 332 (setup 1) or 340 (setup 2) water-immersion objectives. As the images are of 3D culture of cells deep within a hydrogel construct, quantitative morphometric analysis could not be performed. Thus, representative images demonstrating the typical view of cellular protrusions formed were prepared and are presented as 2D projections of the Z-stacks or as 3D rotating projections (Supplemental Movie).
WB
Following dose-response and kinetics analyses (100, 300, 500 ng/ml CCL21; 5 different time points in the range of 2.5-40 min), MCF-7 breast tumor cells were stimulated in suspension by CCL21 (as above; PeproTech) at final concentrations of 100 or 300 ng/ml (or diluent as control) for 5 min (based on kinetics analyses; data not shown). Then, cells were lysed in radioimmunoprecipitation assay lysis buffer, and conventional WB procedures were taken, using rabbit antibodies against the following proteins (all from Cell Signaling Technology, Danvers, MA, USA): phosphorylated Akt (Cat. #9271), Akt (Cat. #9272), phosphorylated Erk (Cat. #4370), Erk (Cat. #4695), and GAPDH served as loading control (Cat. #ab9485; Abcam). Then, membranes were reacted with HRP-conjugated goat anti-rabbit IgG (Cat. #111-035-003; Jackson ImmunoResearch Laboratories), subjected to ECL (Cat. #20-500; Biological Industries), and visualized using a Kodak medical X-ray processor (Carestream Health, Rochester, NY, USA). Bands on immunoblots were quantified by densitometry using TINA image analysis software. When appropriate, before CCL21 stimulation, CCR7-overexpressing breast tumor cells were exposed to TME stimulation for 72 h, as described above.
ELISA CCR7-or CXCR4-overexpressing MCF-7 breast tumor cells were exposed to TME stimulation (or to diluents as control) for 72 h, as described above. CM was removed from the last 24 h of cultures and concentrated 320 by 3 kDa cut-off Amicon Ultra centrifuge filters (Cat. #UFC900324; Merck Millipore, Tullagreen, Ireland). CCL21 or CXCL12 levels were determined by ELISA using standard curves with rhCCL21 or rhCXCL12 (as above; PeproTech) at the linear range of absorbance using the following antibodies: 1) for CCL21, coating anti-CCL21 antibodies (Cat. #500-P109; PeproTech), and anti-CCL21, detecting biotinylated antibodies (Cat. #500-P109Bt; PeproTech); 2) for CXCL12, coating anti-CXCL12 antibodies (Cat. #500-P87A; PeproTech), and anti-CXCL12, detecting biotinylated antibodies (Cat. #500-P87ABt; Pepro-Tech). After the addition of streptavidin-HRP (Cat. #016-030-084; Jackson ImmunoResearch Laboratories), the substrate 3,39,5,59-tetramethylbenzidine-ELISA solution (Cat. #ES001; EMD Millipore, Temecula, CA, USA) was added. The reaction was stopped by addition of 0.18 M H 2 SO 4 and was measured at 450 nm.
In vivo mouse model mCherry-expressing MCF-7 breast tumor cells that also stably expressed CCR7 (or the empty vector as control) were exposed or not exposed in vitro to TME stimulation for 72 h, as described above. Then, the cells were washed in PBS, and 1 3 10 6 live cells were mixed 1:1 with Matrigel (Cat. #356234; BD Biosciences, Franklin Lakes, NJ, USA). Cells were inoculated orthotopically to the mammary fat pad of 6-to 8-wk-old female athymic nude mice (Harlan Laboratories, Jerusalem, Israel). One week before tumor cell inoculation, mice were implanted subcutaneously with slow-release estrogen pellets (1.7 mg/pellet, 60 d release; Cat. #SE-121; Innovative Research of America, Sarasota, FL, USA), which are essential for growth of MCF-7 cells in mice. The CRi Maestro noninvasive intravital imaging system was used weekly to monitor tumor growth in intact mice. Five weeks after inoculation, mice were euthanized, and metastases were detected in excised organs ex vivo by the CRi Maestro device. The excised organs included tumor-adjacent LNs (inguinal), contralateral LNs, leg bones (tibia + fibula), chest bones (sternum + ribs), liver, and lungs. All procedures involving experimental animals were approved by Tel Aviv University Ethics Committee (Permission Number L-14-058) and were performed in compliance with local animal welfare laws, guidelines, and policies. Two experimental repeats were performed, showing similar results, with a total of 8-9 mice/group.
Data presentation and statistical analyses
In vitro experiments were analyzed by 2-tailed unpaired Student's t test and are presented with SD or SEM, as indicated for each figure in the corresponding legend. Sizes of primary tumors developed in mice were compared by 1-way ANOVA, and proportions of mice bearing metastases were compared by Fisher's exact test. Statistical aspects of "3D hydrogel" analyses are described above in the relevant section. Data obtained from the METABRIC dataset were analyzed as indicated above ("Patient dataset"). P , 0.05 values were considered statistically significant.
RESULTS
Analyses of patient data demonstrate a unique pattern of CCR7 expression and of its associations with LN metastases in the luminal-A subtype of breast cancer
We began this study by analyzing patient data, in which we determined CCR7 expression levels and their associations with LN metastasis in different breast cancer subtypes: luminal-A, luminal-B, basal, HER2+, normal-like, and NC. Here, we took advantage of the METABRIC dataset of breast cancer patients [35] , which like other patient datasets is commonly used as a result of its robust, high-throughput characteristics [36] [37] [38] .
Published reports indicate that in breast tumors, CCR7 is predominantly expressed by the tumor cells and not by stroma cells or immune infiltrates (determined by IHC analyses [9, 31] ), supporting our intent to analyze mainly tumor cell-expressed CCR7. To increase the relevance of our analyses, the current study included only patient samples that had a high content of tumor DNA (.70% of the sample DNA). Overall, the study included 973 patients who were divided into the different disease subtypes based on the PAM50 annotation of the dataset, as demonstrated in Table 1 .
First, we determined the proportion of patients with LN metastasis in the different disease subtypes. The findings in Table 1 demonstrate that the frequency of LN dissemination was significantly higher in the 3 more aggressive subtypes-basal, HER2+, and luminal-B-than in the luminal-A subtype. (Note that because the phenotype of the normal-like is not fully established, and the NC group contains only 3 patients, whose categorization was not provided, these 2 groups were included in the analyses, but the implications of their findings were not addressed further in the study.) Whereas 44.4% of luminal-A patients had LN metastases, the proportion of basal, HER2+, and luminal-B patients with LN metastases was significantly higher, $55%. These results are in line with findings provided by other breast cancer cohorts, demonstrating a lower proportion of LN metastasis in luminal-A breast tumors than in other disease subtypes [20-24, 26, 29] , and strengthen the relevance of the METABRIC dataset used in our study.
Then, we determined the expression of CCR7 using the same patient cohort. Here, the METABRIC dataset had a strong advantage over IHC analyses, as it has provided quantitative data that cannot not be obtained by IHC stainings and provided information on .900 patients, a large cohort that can hardly be achieved in biopsy studies of IHC. The histograms of Fig. 1A demonstrate the pattern of CCR7 distribution in each of the different subtypes; they indicate that CCR7 expression levels are broadly distributed and that there is a substantial overlap among the different subtypes. However, differences in distribution patterns were noted: a higher proportion of luminal-A patients was identified in the lower end of the CCR7 expression histogram than in the basal and HER2+ subtypes, indicating that the expression levels of CCR7 are generally lower than in these 2 other subtypes ( Fig. 1A1 and A2 ). In contrast, the expression levels of CCR7 in luminal-A tumors were very similar to those of luminal-B ( Fig. 1A3 ), despite the higher proportion of LN metastasis in the latter ( Table 1) .
The broad distribution of CCR7 expression levels and the overlap among the different subtypes indicated that more refined tools are required to identify better the expression patterns of CCR7 in different groups of patients and their associations with the extent of LN metastasis. Such higher resolution information can be provided by analyzing the extremes-high CCR7-expressors vs. low CCR7-expressors. Thus, we determined the proportion of high vs. low CCR7-expressors in each of the disease subtypes and the way CCR7 expression levels are associated with lymphatic dissemination. To this end, we have used the well-accepted quartile analysis [63] [64] [65] [66] and divided the patient cohort to 4 quartiles on the basis of CCR7 expression levels. Then, we analyzed the 2 extreme quartiles of "CCR7-high" and "CCR7-low" by determining the proportion of patients that belonged to either of these 2 extreme quartiles in each subtype ( Table 2 ; the normal-like and NC groups were gathered together under the term others). This analysis uses deviation from the expected 25% of patients of each subtype in each quartile as indication for association between a specific marker, in this case, CCR7, and disease subtype. The results of Table 2 show strong deviation from the expected 25% for luminal-A patients. Only 13% of luminal-A patients were included in the CCR7-high quartile, and 33.7% of these patients were identified as low CCR7 expressers. Whereas similar results were obtained for luminal-B breast cancer patients (15.4% in CCR7-high quartile; 28.9% in CCR7-low quartile), an opposite deviation trend was obtained for the basal and HER2+ patients. Included in the CCR7-high quartile were 47.6% of basal patients and 41.4% of HER2+ patients, whereas only 12.5% of the basal patients and 15.6% of HER2+ patients were included in the CCR7-low quartile.
The findings provided above demonstrated that luminal-A patients expressed CCR7 in similar levels to luminal-B patients ( Fig. 1A and Table 2 ), but the proportion of LN metastasis in luminal-B was significantly higher than in luminal-A (Table 1) . To provide insights to the reasons that may account for differences between luminal-A and luminal-B patients, we analyzed the associations between LN dissemination and CCR7 expression in each subtype. The analyses revealed major differences between these 2 groups of patients ( Table 3) . Whereas the incidence of LN metastasis was not statistically different in luminal-A patients expressing high CCR7 levels (45.2%) compared with patients expressing low CCR7 levels (40.5%; P = 0.532), in luminal-B breast cancer patients, LN metastatic levels were significantly associated with high CCR7 expression: 60.8% in the CCR7-high quartile vs. 44.6% LN+ in the CCR7-low quartile (P = 0.048). Furthermore, because the luminal-B subtype is often categorized as HER2+, we performed a multivariate analysis that demonstrated that the association between HER2 expression and LN metastasis in luminal-A and luminal-B was not significant (P = 0.74). Of note, subtype-specific analyses for associations between LN metastases and CCR7 status were performed also for the basal and HER2+ subtypes. As a result of the low number of patients in the CCR7-high and CCR7-low quartiles in each of these subtypes, the results did not reach statistical significance, although a trend toward association between LN dissemination and high CCR7 expression was revealed also in the basal subtype (data not shown).
Taken together, the results in this part of the study indicate that a relatively high proportion of basal and HER2+ patients expresses high levels of CCR7 and has developed LN metastasis ( Fig. 1 and Tables 1 and 2 ). The refined quartile analysis (Table 3 ) demonstrated that in luminal-B patients, patients with higher levels of CCR7 tended to develop LN metastases more than patients with lower expression levels of CCR7. These results are in line with the suggested roles of tumor cell-expressed CCR7 in promoting lymphatic dissemination in cancer. However, in luminal-A patients, a different pattern was revealed, as the incidence of LN metastasis was similar for high CCR7-expressors and low CCR7-expressors, and expression of high levels of CCR7 did not provide advantage to the tumor cells in disseminating to LNs ( Fig. 1 and Tables 1-3 ).
These findings suggest that a different regulatory pattern exists in luminal-A patients, which was also revealed in analyses of the CXCR4-CXCL12 axis. As with CCR7, luminal-A breast cancer patients demonstrated a general trend of lower CXCR4 levels Data analyses were performed using the METABRIC dataset, including only patient samples that had high content of tumor DNA (.70% of the sample DNA; 973 patients). All patients included in the cohort were classified according to their subtypes, according to the PAM50 annotation file. Then, within these groups, the numbers and percentages of LN+ patients were determined (based on the PAM50 file). x 2 statistical analyses (not providing pairwise comparisons) indicated that the proportions of patients with LN metastases differed significantly within the subtypes [luminal-A and normal-like were clearly lower than the other than the basal and HER2+ subtypes (Supplemental Fig. 1A and B ). Furthermore, as was revealed for CCR7, the expression levels of CXCR4 in luminal-A were similar to luminal-B (Supplemental Fig.  1A and B ), but only in luminal-B patients was lymphatic dissemination significantly associated with high expression levels of CXCR4 (P = 0.032; Supplemental Fig. 1C ). In contrast, in luminal-A patients, there was no difference in lymphatic dissemination between patients with high or low expression levels of CXCR4 (P = 1; Supplemental Fig. 1C ). These findings point to a unique mode of regulation, not only of CCR7-related axes but also of CXCR4-related pathways, which require improved mechanistic understanding, as we have followed with respect to the CCR7-CCL21 axis, which is known to be of particular importance in determining LN metastasis.
Luminal-A breast tumor cells exposed to TME stimulation demonstrate a lower ability to migrate and to form directional protrusions in response to CCL21, but this is not a result of TME-induced CCR7 internalization
The different roles of the CCR7-CCL21 axis in regulating lymphatic dissemination of luminal-A breast tumor cells may be dictated by the TME of the primary tumor and by the way such TME signals are interpreted by luminal-A breast tumor cells. To address this possibility, we asked how factors residing in the TME of primary breast tumors affect the response of luminal-A breast tumor cells to CCL21-mediated chemotactic cues, which usually trigger migration and homing of CCR7-expressing tumor cells to LNs. To study the regulation of CCR7-mediated migratory responses by factors of the primary TME, we used the 2 most acceptable models of human luminal-A breast tumor cells: MCF-7 and T47D cells (more reasons for using these cells are given in Materials and Methods, under Cell cultures). These 2 cell lines responded similarly to TME stimulation imposed by joint exposure to estrogen + TNF-a + EGF, as manifested by cell remodeling, accompanied by formation of cellular protrusions, cell dispersion, and elevated percent of tumor cells that coexpress the adhesion molecules b1 and CD44. (MCF-7 cells were demonstrated in our published study [53] , and T47D cells are demonstrated in Supplemental Fig. 2A and B.) First, we analyzed the migration of MCF-7 cells in response to CCL21 and the impact of TME stimulation on this process. MCF-7 cell migration was assayed in different time points (see Materials and Methods), but overall, they have demonstrated only a low ability to migrate in response to CCL21 ( Fig. 2A; represented by empty vector-expressing cells). This migratory phenotype may reflect only low cell-surface expression levels of endogenous CCR7, which were actually undetectable by FACS or confocal analyses (Fig. 1B) . Such low cell-surface expression levels on MCF-7 cells (that could not be compared with METABRIC expression levels of CCR7 in luminal-A patients as a result of technical considerations related to intrinsic properties of dataset preparation) agrees well with other studies that generally demonstrated the expression of CCR7 at the mRNA level or in whole-cell lysates by WB but did not demonstrate substantial cell-surface expression of the receptor [12, [67] [68] [69] [70] [71] .
As our planned experiments required tumor cells that express highly functional CCR7, we have overexpressed CCR7 in the MCF-7 cells (Fig. 1B) . Titration experiments of migration were performed in the range of 75-500 ng/ml CCL21 (Supplemental Fig. 3A) , following which the concentration of 300 ng/ml was selected for further studies. This concentration agrees well with other studies describing optimal migration of tumor cells mainly in response to relatively high chemokine concentrations (e.g., for CCL21 and CXCL12 [72, 73] ). Under these conditions, CCR7-overexpressing cells have demonstrated substantial and reproducible migration capacity in response to CCL21 ( Fig. 2A) . Data analyses were performed using the METABRIC dataset, including only patient samples that had high content of tumor DNA (.70% of the sample DNA; 973 patients; the term others includes normal-like and NC patients). All patients included in the cohort were classified into CCR7-low and CCR7-high, corresponding to the first (lower) and fourth (upper) quartiles of expression, respectively (based on the PAM50 annotation file). Then, in the CCR7-low quartile, consisting of 243 patients, the number of luminal-A patients was determined (114 patients), and its fraction out of the whole luminal-A population (338 patients) was calculated (33.7%). A similar process was performed for all other disease subtypes in the CCR7-low and CCR7-high quartiles. Data analyses were performed using the METABRIC dataset, including only patient samples that had high content of tumor DNA (.70% of the sample DNA; 973 patients). All patients included in the cohort were first classified according to their subtypes (based on the PAM50 annotation file). Then, patients were classified based on CCR7 expression and divided to quartiles. The table compares the proportion of patients with LN metastases in the CCR7-low and CCR7-high quartiles, corresponding to the first (lower) and fourth (upper) quartiles of expression. Proportions were compared using 2-sided x 2 test. NS, Not significant. a CCR7-low compared with CCR7-high in each subtype.
Then, we asked how stimulation by factors residing at the TME of primary luminal-A tumors would impact the ability of luminal-A breast tumor cells to migrate in response to CCL21. To analyze this aspect, luminal-A CCR7-overexpressing MCF-7 breast tumor cells were exposed to estrogen + TNF-a + EGF (TME stimulation) for 72 h. The doses of these factors and duration of stimulation were determined in our previous study, in which they were found to have a major impact when they were all combined, endowing MCF-7 cells with metastasis-related functions and high metastatic activities in vivo [53] .
The findings in Fig. 2B indicate that following such a simultaneous stimulation by estrogen + TNF-a + EGF, the migration of CCR7-overexpressing cells toward CCL21 was reduced significantly. In 4 experimental repeats, TME stimulation has led to 62 6 8% reduction in cell migration in response to CCL21. The data of Fig. 2B imply that TME stimulation has perturbed, to some extent, general migratory properties in the tumor cells (migration to medium, marked as "-"), but this possibility was not supported by additional findings obtained in this study or in its preceding one [53] . In contrast, the inhibition of CCL21-induced migration by TME factors was corroborated by all additional study results demonstrated below.
In parallel, we have analyzed the basal and CCL21-induced migratory responses of T47D cells. As a result of the lack of expression of endogenous CCR7 in the cells, we overexpressed CCR7 (Supplemental Fig. 2C ) and determined their migration in response to CCL21, with and without TME stimulation. Without TME stimulation, T47D demonstrated low basal migration and failed to respond to CCL21-induced gradients (positive controls of other cells migrated nicely to the recombinant chemokine; data not shown). Moreover, TME-stimulated T47D cells demonstrated a "patchy" pattern of basal migration (without CCL21; Supplemental Fig. 2D2 ). Under these conditions, it was impossible to quantitate the impact of TME stimulation on CCL21-induced migration (data are not shown). The lack of response of CCR7-overexpressing T47D cells to CCL21 (without TME stimulation) provides more evidence of modified regulation of the CCR7-CCL21 axis in luminal-A cells, as demonstrated in MCF-7 cells. However, they also illustrate technical difficulties; thus, the study was followed with MCF-7 cells only.
As CCR7 is a G protein-coupled receptor, regulated by processes of ligand-induced internalization [74] [75] [76] [77] , we asked whether CCR7 undergoes such a ligand-driven process in tumor cells exposed to TME stimulation. The findings of Fig. 3A demonstrate that CCL21 was not detected in the growth medium of tumor cells, even after TME stimulation. In addition, CCR7 surface expression levels were not reduced by TME stimulation (Fig. 3B and Table 4 ), further negating the possibility that ligandinduced CCR7 internalization has taken place in response to TME stimulation and that such a process was responsible for the lack of CCL21-responsiveness in TME-stimulated cells.
Of note, following TME stimulation, the expression of endogenous CCR7 was not increased in the cells (as demonstrated in vector-expressing cells; Fig. 3B1 ), but it was markedly elevated in CCR7-overexpressing cells ( Fig. 3B2 and Table 4 ). This effect probably reflects the fact that the CMV promotor, used to drive the expression of exogenous CCR7, contains several binding sites to NF-kB, a transcription factor that is strongly activated by TNF-a (which is part of TME stimulation). It was expected that such an increased expression of CCR7 would amplify the ability of TME-stimulated CCR7overexpressing cells to migrate in response to CCL21 (as shown for other chemokine receptors, e.g., [78, 79] ); rather, the chemotactic response was reduced (Fig. 2B) , further emphasizing the fact that the CCR7-CCL21 axis is differently regulated in luminal-A breast tumor cells.
All of the above findings suggest that factors of the primary TME restrain CCL21-induced migration of luminal-A breast tumor cells and that this phenomenon is not a result of TME-induced CCR7 internalization. We indicate that similar findings were obtained also for the CXCR4-CXCL12 pair: TME stimulation has reduced CXCL12-induced migration of CXCR4-expressing MCF-7 cells (Supplemental Fig. 4B ) but did not induce CXCL12 release to CM Migration of CCR7-overexpressing MCF-7 luminal-A breast tumor cells to CCL21, with or without TME stimulation. CCR7-overexpressing cells were exposed for 72 h to TME stimulation (estrogen, 10 28 M; TNF-a, 50 ng/ml; EGF, 30 ng/ml) before migration assay. "No TME stimulation," Cells grown for 72 h in the presence of diluents. Assay was carried out as described in A. (A and B) Mean 6 SEM of n $ 4 independent experimental repeats is presented. NS, Not significant.
(Supplemental Fig. 4C ). TME stimulation has also induced the expression of exogenous CXCR4 and did not affect the expression of the endogenous receptor (that was rarely detected in MCF-7 cells at the cell membrane also in other studies; Supplemental Fig. 4D ). Thus, luminal-A breast tumor cells are endowed with unique responses to several metastasis-related chemotactic cues and not only to CCL21.
TME factors prevent the formation of directional protrusions in response to CCL21 gradients
The findings presented above led us to investigate the molecular mechanisms that may give rise to described reduced migratory responses of luminal-A breast tumor cells to CCL21 following TME stimulation. Cells migrating in response to chemotactic cues are known to develop cellular protrusions in the direction of the high concentration of the chemokine [16, 80] . To follow on the above-presented migration results, we asked if the formation of such CCL21-induced directional protrusions by luminal-A breast tumor cells is perturbed by TME stimulation. To envision such protrusions, we developed a novel single-cell analysis system based on 3D hydrogel (Supplemental Fig. 5 ). When the original MCF-7 cells were exposed to TME stimulation, they formed large cellular protrusions (Fig. 4A) , in line with our published findings showing that similar TME stimulation has led to formation of cellular protrusions in 2D analyses and to tumor cell spreading and scattering [53] . As such robust protrusions could have hindered our ability to detect the formation of directional cellular protrusions formed in response to CCL21, in studies with CCL21, the stimulation by TME factors was reduced to 16 h. Under these conditions, tumor cells that overexpressed CCR7 and were not exposed to TME stimulation formed defined protrusions in the direction of the high concentration of CCL21 (Fig. 4B1, lower right, and B2, upper right, and Supplemental Movie-Part 1). However, when these CCR7-overexpressing cells were exposed to TME stimulation, the CCL21-induced directionality was totally lost, and small cellular protrusions were coming out of the cells in an unordered manner, as shown in Fig. 4B2 , lower right, and in the Supplemental Movie-Part 2.
Therefore, whereas TME factors generally induced formation of large cellular protrusions in the absence of CCL21 stimulation (Fig. 4A) , they hampered the creation of directional protrusions in response to chemotactic cues delivered by CCL21 (Fig. 4B2 ). Reduced formation of CCL21 directional responses may stand at the basis of the down-regulation of CCL21-induced migration, imposed on CCR7-overexpressing cells by TME stimulation, as shown above in Fig. 2B .
In cells prestimulated by TME factors, CCL21 does not activate efficiently the PI3K and MAPK pathways
With the further analysis of the mechanisms of CCR7 activities in luminal-A breast tumor cells, we speculated that migration-relevant signaling pathways could not be fully activated by CCL21 in cells that have been prestimulated by TME factors. Each of the TME factors used in our study-estrogen, TNF-a, and EGF-was found to induce the activation of the PI3K and MAPK pathways in MCF-7 cells [59, 81, 82] ; furthermore, these 2 signaling cascades are generally involved in migration and are activated by ligand binding to CCR7 in other settings [83] [84] [85] . Therefore, we began this part of the study by asking if the PI3K and MAPK pathways take part in CCL21-induced migration of CCR7-overexpressing breast tumor cells. By inhibiting the activation of these 2 signaling cascades ( Fig. 5 and Table 5 ), we found that the PI3K and also partly the MAPK cascade were required for CCL21induced migration of CCR7-overexpressing MCF-7 breast tumor cells. The mean 6 SD of percent CCR7-positive cells and of mean fluorescence intensity (MFI) values obtained in n = 4 independent experimental repeats. The expression of cell-surface CCR7 was determined by FACS analyses, using specific antibodies.
Then, we determined the impact of TME stimulation on activation of the PI3K and MAPK pathways by CCL21. To recapitulate the conditions used in migration assays, CCR7overexpressing cells were exposed to TME stimulation for 72 h. Then, the cells were stimulated for 5 min by 100 or 300 ng/ml CCL21 (selected based on dose-response and kinetics experiments, as detailed in Materials and Methods). These CCL21 concentrations are suboptimal and optimal, respectively, for induction of CCL21-induced migration of CCR7overexpressing MCF-7 cells (which are not exposed to TME stimulation; Supplemental Fig. 3A ). This step was followed by determination of the activation levels of Akt and Erk by WB. Here, we found that TME stimulation has induced potent activation of Akt and Erk (Akt: Fig. 6A and B1 ; Erk: Fig. 7A   Figure 4 . TME factors generate robust global cellular protrusions in luminal-A breast tumor cells but disrupt the formation of CCL21-directed protrusions. (A) Generation of cellular protrusions upon exposure to TME stimulation. mCherry-expressing MCF-7 luminal-A breast tumor cells were mixed with PEG-fibrinogen and cross-linked by photopolymerization to create the 3D hydrogel scaffold. Medium containing the TME stimulation (as in Fig. 2 ) or diluents in No TME stimulation was added on top of the hydrogel for 72 h. (B) Disruption of CCL21-directed cellular protrusions by TME stimulation (as illustrated also in Supplemental Movie). (B1) mCherry-expressing MCF-7 breast tumor cells that also overexpressed CCR7 (or the empty vector as control) were mixed with PEG-fibrinogen and distributed around the chemokine-releasing bead (600 ng CCL21 or diluent-releasing bead as control). (B2) mCherry-expressing MCF-7 breast tumor cells that also overexpressed CCR7 were exposed to medium containing the TME stimulation (or diluents as control) that was added on top of the hydrogel in the presence or absence of a CCL21-or diluent-releasing bead (as above). (B) The direction of gradient is demonstrated, from the top of the image and downward, and the incubation time was reduced to 16 h to discriminate between the TME-induced process that takes 72 h to complete and the more-rapid chemokine-induced process. In all panels, Z-stack images were obtained by confocal microscopy using a 332 (A) or 340 (B) water-immersion objective. Images were prepared as 2D projections of the Z-stacks. Original images contained several cells and were cropped to show a single cell/image. In all panels, representative images are presented out of n $ 3 independent experiments, each analyzing several cells/group. and B1). In parallel, CCL21 induced the activation of Akt and Erk in CCR7-overexpressing cells, which were not prestimulated by TME signals (Figs. 6A and 7A and 6B2 and 7B2 in "No TME stimulation"). However, when CCL21 stimulation was imposed on cells that had been pre-exposed to TME stimulation, CCL21 did not induce effective activation of Akt and Erk (Figs. 6A and 7A and 6B2 and 7B2 in "TME stimulation").
As Akt and Erk are usually activated rapidly after exposure to stimulators, their elevated phosphorylation after 72 h of TME stimulation reflects a sustained process of activation, which is continuous over time, as shown above, and cannot be further increased by CCL21 stimulation. Published findings demonstrated that estrogen, TNF-a, and EGF, each alone, can induce the activation of Akt and Erk in MCF-7 cells and demonstrated the ability of TNF-a to activate Erk continuously over the time range of 16 h [59, 81, 82] . As all 3 factors together were found to be more effective than each alone in inducing tumor-promoting functions and in vivo metastasis of luminal-A breast tumor cells [53] , these findings propose that the combined activation by the 3 factors together leads to the strong activation of Akt and Erk, which is sustained by TNF-a. To conclude, our findings suggest that TME stimulation has saturated the activation levels of Akt and Erk; thus, they could not be potentiated further by CCL21. This perturbation in CCL21-induced signaling could stand as the basis of the reduced ability of TME-stimulated cells to migrate and to generate directional protrusions in response to CCL21 (Figs. 2B and 4B2, respectively) .
TME factors put constraints on LN metastasis and divert the metastatic spread to distant organs in vivo
To follow these observations, we were interested to see how TME stimulation would affect the formation of metastases in LNs, known to express CCL21 constitutively (also in athymic mice, as we have used in the current study [86] [87] [88] ). MCF-7 cells were described previously as cells with relatively low metastatic potential in in vivo studies using gross measures to determine metastasis. However, with improved detection techniques, based on tumor cell tagging with fluorescent proteins and their detection by the sensitive CRi Maestro device, MCF-7-generated metastases could be detected in specific experimental groups, as shown in our published study [53] and in the current research ( Fig. 8) . Supplemental Fig. 3B demonstrates the primary tumors and metastases formed by MCF-7 cells, as detected by the CRi Maestro device.
In this part of the study, 4 experimental groups of MCF-7inoculated mice were included (a total of 8-9 mice/group in 2 independent biologic repeats that gave rise to similar results): 1) control empty vector-expressing cells, not exposed to TME stimulation; 2) control empty vector-expressing cells, exposed to TME stimulation; 3) CCR7-overexpressing cells, not exposed to TME stimulation; and 4) CCR7-overexpressing cells, exposed to TME stimulation. All tumor cells expressed mCherry to enable monitoring of primary tumors and metastases by intravital imaging and were inoculated orthotopically to the mammary fat pad of athymic mice. At the endpoint of the experiment, as instructed by animal welfare laws (5 wk after inoculation), mice were euthanized, organs were excised, and metastases were determined ex vivo.
Whereas the size of primary tumors did not differ in the 4 groups of mice (Fig. 8A) , a strong impact was revealed for the TME stimulus on the metastatic phenotype of CCR7-overexpressing cells Summary of migration values obtained in each of the 3 independent experiments performed. In each experiment, the values are mean 6 SD of the replicate counts in each experimental group. Mean 6 SEM is presented when the 3 independent experiments were summarized together. For normalization purposes, cells treated by DMSO that migrated to control medium were given the value of 1. LY, LY294002; PD, PD98059. Control cells were incubated with DMSO, the solubilizer of the drugs. A representative experiment of n = 3 is presented. ***P , 0.001 for differences among cells migrating to CCL21 and DMSO-treated cells migrating to control medium. (Fig. 8B2 ). First, with the analysis of tumor cell dissemination to tumor-adjacent LNs, we found that prestimulation of the tumor cells by TME factors alone (Group 2; Fig. 8B1 ) led to increased metastasis formation in tumor-adjacent LNs compared with control mice (78% in Group 2 compared with 50% in Group 1). This impact of TME stimulation agrees well with our published report, demonstrating that upon exposure to TME stimulation in vitro for Figure 6 . TME stimulation induces sustained activation of Akt, which cannot be effectively elevated by CCL21. MCF-7 CCR7-overexpressing luminal-A breast tumor cells were exposed to TME stimulation (as in Fig. 2 ) for 72 h. Cells were then stimulated in suspension by 100 or 300 ng/ml CCL21 for 5 min (time point was selected by kinetics analyses; see Materials and Methods). No TME stimulation, Cells grown in the presence of diluents. Akt phosphorylation was determined by WB. (A) A representative immunoblot of n = 3 is presented. (B) Densitometry analysis of Akt phosphorylation (p-Akt/Total Akt), summarizing n = 3 independent experiments (mean 6 SD). The following treatments were given the value of 1 for normalization purposes: (B1) cells not stimulated by TME factors; (B2) cells that were not exposed to CCL21. *P , 0.05. Figure 7 . TME stimulation induces sustained activation of Erk, which cannot be effectively elevated by CCL21. MCF-7 CCR7overexpressing luminal-A breast tumor cells were exposed to TME stimulation (as in Fig. 2 ) for 72 h. Cells were then stimulated in suspension by 100 or 300 ng/ml CCL21 for 5 min (time point was selected by kinetics analyses; see Materials and Methods). No TME stimulation, Cells grown in the presence of diluents. Erk phosphorylation was determined by WB. (A) A representative immunoblot of n = 3 is presented. (B) Densitometry analysis of Erk phosphorylation (p-Erk/Total Erk), summarizing n = 3 independent experiments (mean 6 SD). The following treatments were given the value of 1 for normalization purposes: (B1) cells not-stimulated by TME factors; (B2) cells that were not exposed to CCL21. *P , 0.05. 72 h, luminal-A MCF-7 cells acquired an increased ability to form metastases at remote organs (note that LN metastases were not investigated in that study [53] ). In parallel, as expected from stable overexpression of functional CCR7 by the tumor cells, CCR7overexpressing MCF-7 cells had a higher ability to metastasize to LNs (88% in Group 3 compared with 50% in Group 1). As the LNs constitutively express CCL21, this pattern is in line with other published studies of lymphatic dissemination of CCR7-expressing tumor cells [9, 12, 89] . However, despite the fact that each of the elements alone-TME stimulation or CCR7 overexpressionelevated the extent of LN infiltration, the incidence of LN metastasis was not increased any further when these 2 elements were combined. Thus, when CCR7-overexpressing cells were preexposed in vitro to TME stimulation, the extent of LN metastasis was 78% (Group 4), similar to TME stimulation alone (Group 2; 78%) and to CCR7 overexpression alone (Group 3; 88%).
Most importantly, analyses of tumor cell spreading to contralateral LNs have provided additional, strong evidence for the lack of cooperativity between the TME and CCR7 pathways. Whereas TME stimulation and CCR7 overexpression, each alone, led to an increase in the proportion of mice with metastases in contralateral LNs (13% of control mice in Group 1; 33% of TME-stimulated tumor cells in Group 2;, 38% of CCR7-overexpressing cells in Group 3), the extent of LN metastasis in contralateral LNs was not further increased when both TME stimulation and CCR7 overexpression were combined (33% of mice in Group 4) . As our in vitro studies (Figs. 2, 4 , 6, and 7) had clearly indicated that TME stimulation has saturated Akt and Erk signaling, and thus, CCL21-mediated migratory signals could not come into effect, the current results suggest that the responsiveness of CCR7-expressing tumor cells to CCL21-induced homing signals was also reduced in vivo. Thus, on the background of strong TME activation, no cooperativity could have been obtained by CCL21 homing signals, and the extent of LN metastasis was not increased when both pathways were combined.
Then, we assessed the formation of distant metastases in each of the 4 groups of mice (Fig. 8B2) . With the analysis of metastases in tibia/fibula (leg bones), we found that in line with our published study [53] , the TME-stimulated tumor cells in Group 2 formed higher levels of remote metastases compared with control cells of Group 1 (56% in Group 2 vs. 25% in Group 1). Furthermore, CCR7-overexpressing cells that had not been exposed to TME stimulus (Group 3) were more metastatic than the control cells of Group 1 (50% in Group 3 vs. 25% in Group 1), in line with reports on the ability of the CCR7-CCL21 axis to support not only dissemination to the LNs [6, 9, 12] but also to bones [10] . The most interesting finding was obtained when CCR7-overexpressing cells were pre-exposed to TME stimulation (Group 4). Here, a prominent increase was found in formation of tibia/fibula metastases, reaching incidence of 89% of mice in Group 4 compared with 25% in Group 1, 56% in Group 2, and 50% in Group 3. A similar trend toward an increase in the metastatic pattern in mice of Group 4 was also revealed when leg The figure shows that the increase in LN metastasis (B1) was similar in Groups 2-4, and as expected, the differences between the groups were not significant. In bone metastases (B2), a substantial elevation in Group and chest bones (All bones) were analyzed together for the presence of metastases. These results agree well with published findings demonstrating that the bone is the preferred distant metastatic site in luminal-A breast cancer patients, which correlates with poor prognosis [23, 26, 27] . Of note, sporadic micrometastases in the lungs were detected in mice of all groups in mostly similar incidences, whereas an increased tendency of colon metastases was observed in mice of Group 4 (not shown, as the incidence was not high enough to allow proper comparison), in line with the above-described increase in bone metastases in this group.
Taken together with our in vitro findings demonstrating that CCR7-CCL21 signals cannot come into effect in luminal-A breast tumor cells that have been prestimulated by TME factors, the current in vivo results indicate that CCL21 chemotactic cues that act constitutively in the LN [86] [87] [88] are not productive in attracting CCR7-expressing luminal-A breast tumor cells that have been exposed to TME stimuli; thus, CCL21-homing cues do not act in cooperativity with TME factors in inducing LN metastasis. The elevated incidence of bone metastases imposed by TME prestimulation on CCR7-overexpressing cells (Group 4) suggests that when CCR7-overexpressing cells fail to respond to homing signals originating at the LNs, they can better react to homing and tumor-seeding signals delivered by distant organs, such as bones (see Discussion). Thus, the TME of the primary tumor promotes metastatic spread of luminal-A breast tumor cells to distant sites and drives disease progression.
DISCUSSION
In this study, we provide novel information on the regulation of CCR7-CCL21-induced metastatic dissemination in a specific subtype of breast cancer patients, instead of the general approach taken so far. Specifically, we demonstrate that CCL21induced chemotactic cues act in a unique manner in the luminal-A subtype of breast cancer and suggest that CXCL12-mediated cues are also regulated differently in this subgroup of patients compared with other disease subtypes. Together, these findings propose a general theme in which luminal-A breast tumor cells interpret metastasis-relevant chemokine cues in a unique manner.
In general, the LN status presents an important prognostic factor in breast cancer [21] ; however, recent findings and results of our study indicate that LN metastases are generally less prevalent in luminal-A tumors than in the more aggressive subtypes of disease [20] [21] [22] [23] [24] [25] [26] . Rather, retrospective studies indicate that luminal-A tumors show the highest propensity to metastasize to bones, mainly when compared with the basal subtype of breast cancer [23, 26, 27] . From a clinical point of view, bone metastases predict poor survival [27, 90] and are extremely difficult to treat. These findings raise questions on the mechanisms controlling the metastatic spread of luminal-A breast tumor cells and their preference toward bones instead of LN dissemination.
In the present study, we provide mechanistic insights to the higher propensity of bone metastasis than LN metastasis in luminal-A patients, combining patient data, in vitro studies, and an in vivo model system of luminal-A breast cancer. In line with the findings obtained in vitro and in vivo, showing that CCR7 functionality is restrained by stimulation with TME factors, the patient dataset indicates that high CCR7 expression in luminal-A tumors does not provide an advantage for lymphatic dissemination. Furthermore, our in vitro and in vivo findings suggest that when CCR7 is expressed by the tumor cells in luminal-A patients, the tumor cells interpret the signals of the TME in a unique manner that precludes efficient activation of CCR7 by its ligand. Specifically, we demonstrate that factors of the primary TME induce a sustained activation of migration-related signaling pathways that cannot be further activated by CCL21; thus, the TME puts constrains on CCL21-mediated signaling and migratory processes in vitro and in vivo. Under these conditions, in which CCL21-induced chemotactic cues are not fully active in vivo, the cells possibly undergo hematogenous dissemination through blood vessels and more easily respond to bone-residing factors that facilitate metastasis formation in bones.
The preferential dissemination of luminal-A breast tumor cells to bones illuminates the need to identify the factors that may promote the homing, seeding, and proliferation of the tumor cells in remote organs. Our results suggest that the CXCR4-CXCL12 axis may not optimally operate in luminal-A tumors; thus, a more general shift in the overall response of chemokineinduced metastasizing signals may be taking place in this subtype of disease. It is possible that in this group of patients, nonchemokine factors are active at distant sites, including bones. The mechanisms mediating such processes need to be elucidated further in separate studies, but several options may exist. For example, it is possible that luminal-A cells that are constantly exposed concomitantly to several arms of the TME, as recapitulated by the TME stimulation used in this study, release factors that eventually promote the formation of metastatic niches specifically in bones. Findings by Massagué and coworkers [91] have shown that CXCL8, which is highly released by luminal-A cells exposed to our TME stimulation [53] , promotes self-seeding of circulating cancer cells. Another possibility is that TME stimulation triggers changes in expression of various adhesion molecules that may lead to preferential capturing of cancer cells in remote organs, as has been demonstrated for integrin-mediated processes [92] . TME stimulation may have also induced, via induction of CD44 expression (as shown in our published study [53] ), CD44-dependent conditioning of premetastatic niches by exosomes [93] .
Our study also emphasizes the importance of signals provided by factors of the primary tumor, in dictating the metastatic phenotype of tumor cells. The ability of TME signals to influence tumor progression is determined by the way they are interpreted by cancer cells and by the intrinsic setup of the tumor cells. For example, when the TME of the primary tumor is enriched with estrogen, luminal-A (ER+) but not basal (ER2) breast tumor cells would respond to estrogen-delivered signals. Likewise, luminal-B tumor cells that express lower levels of ER or PR (or can be devoid of each of them, as indicated in some of the categorizations) and are endowed with a higher proliferation rate than luminal-A cells (Ki-67) may respond differently to TME factors than luminal-A tumors.
Indeed, we found that luminal-A and luminal-B tumors displayed different association patterns between CCR7 expression and LN metastasis. Whereas the CCR7 pathway may not necessarily be involved in lymphatic dissemination in luminal-A patients, it might be highly relevant for the luminal-B group of patients (Table 3 ). This finding is even more intriguing, considering that the average CCR7 expression levels are comparable in the 2 groups of patients (Fig. 1A) . The significant correlation between high CCR7 levels and the elevated proportion of LN involvement in luminal-B patients could be explained by the intrinsic properties of luminal-B cells. These cells are more aggressive, their proliferation rate is, by definition, higher compared with luminal-A cells, and their growth is less hormone-dependent. Therefore, it is possible that in luminal-B cells, TME signals are interpreted differently than in luminal-A cells, and thus, TME factors do not impair the responsiveness of luminal-B cells to CCR7-CCL21-mediated chemotactic cues.
Obviously, the regulation of tumor cell response to chemotactic cues may have strong clinical relevance. Other studies suggested using CCR7 expression as a prognostic marker during breast cancer diagnosis and as a potential therapeutic target [1, 9, 94] . Our findings imply that such possibilities may not be appropriate for luminal-A breast cancer patients. Our observations thus concur with other studies that had not found correlation between CCR7 expression and metastasis occurrence [95] , implying that CCR7 alone would not be a reliable marker for predicting dissemination to LNs, distant metastasis development, or overall survival. Therefore, the repertoire of chemokine receptors that are expressed by tumor cells should be regarded combined with improved knowledge of the TME constituents that determine the responsiveness of the cancer cells to chemotactic cues and thus, impact disease progression. Such an approach is more personalized and therefore, may offer patients a more accurate diagnosis and more importantly, more effective therapies. AUTHORSHIP P.W. carried out most in vitro and all in vivo experiments and drafted the manuscript. T.M. constructed the CCR7 and CXCR4 vectors. O.K. performed the experiments with 3D hydrogels, supervised by D.S. C.K. and S.W. provided data analyses of human cancer datasets. D.F.L. provided conceptual input and materials to the study. A.B.-B. was the principal investigator, responsible for study conception and design and for complete manuscript preparation. All authors read and approved the manuscript.
